Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 2;42(25):3033–3046. doi: 10.1200/JCO.23.02233

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG A5. — DCs decreased by treatment and association with survival in CaboNivoIpi. (A) Percentage of CD141+ mDCs decreased. (B) Higher percentage of CD141+ mDCs at baseline was associated with better OS with CaboNivoIpi. (C) Percentage of CD1c+ mDCs decreased. (D, E) Higher fold change in percentage of CD1c+ mDCs at C2D1 was associated with better (D) PFS and (E) OS with CaboNivoIpi. (F) Percentage of CD303+ pDCs decreased. FC, fold change; mDC, mDC, myeloid dendritic cells; OS, overall survival; PFS, progression-free survival.